Mimpara (Cinacalcet)

Cinacalcet, the active ingredient in Mimpara, is a calcimimetic presented as an oral tablet for oral use. It treats secondary hyperparathyroidism in dialysis patients, primary hyperparathyroidism when surgery is not an option, and hypercalcemia linked to parathyroid carcinoma.

GNH USA supplies Mimpara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for patients across multiple markets. Our global network ensures timely delivery and compliance with local pharmaceutical standards.

Mimpara (cinacalcet) acts on the calcium‑sensing pathway to control parathyroid hormone excess.

- Secondary hyperparathyroidism (dialysis patients): lowers PTH levels, helping maintain calcium and phosphate balance. - Primary hyperparathyroidism (non‑surgical candidates): reduces serum calcium by decreasing PTH secretion. - Hypercalcemia associated with parathyroid carcinoma: controls elevated calcium levels through PTH suppression.

Cinacalcet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes of stomach emptying. - Diarrhea: loose stools that may affect hydration. - Constipation: reduced bowel movements. - Muscle cramps: transient painful tightening of muscles. - Hypocalcemia (asymptomatic or mild): low blood calcium without severe symptoms.

Serious or Rare Side Effects: - Severe hypocalcemia leading to seizures or cardiac arrhythmias: dangerously low calcium levels. - Skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe blistering and skin loss. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe allergic reactions (anaphylaxis): rapid onset of breathing difficulty and swelling. - Persistent vomiting causing dehydration: prolonged loss of fluids.

When prescribing Mimpara, clinicians should consider several safety measures to minimize risks and ensure therapeutic effectiveness.

- Monitor serum calcium and phosphorus: check levels regularly to adjust dose. - Adjust dose in renal impairment: reduced kidney function may alter drug clearance. - Use caution in patients with cardiac disease: hypocalcemia can affect heart rhythm. - Avoid use in pregnancy unless benefits outweigh risks: limited data on fetal safety. - Review concomitant medications: assess for interactions that may affect cinacalcet levels. - Educate patients on signs of low calcium: report muscle cramps, tingling, or seizures promptly. - Store at room temperature: keep in the original pack, protect from moisture.

Cinacalcet interacts with several drugs that can alter its plasma concentration or its calcium‑lowering effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase cinacalcet exposure and risk of hypocalcemia. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce cinacalcet levels, diminishing efficacy. - Calcium supplements taken concurrently: can counteract the drug’s intended calcium reduction.

Moderate Interactions (Monitor Closely): - Vitamin D analogues (e.g., calcitriol): may enhance calcium lowering, requiring closer monitoring. - Loop diuretics (e.g., furosemide): can affect calcium balance and may increase hypocalcemia risk. - Bisphosphonates: combined effect on calcium may necessitate dose adjustments.